1-1 of 1
Bettina Wulff Risør
Close
Sort by
Journal Articles

Cost-Utility of Venetoclax Plus Obinutuzumab for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia without Del17p/ TP53 -Mutation Compared to Chlorambucil Plus Obinutuzumab

Matilde Slot, Carsten Utoft Niemann, Bettina Wulff Risør, Lars Holger Ehlers, Emelie Rotbain
Journal: Blood
Blood (2022) 140 (Supplement 1): 2163–2164.
https://doi.org/10.1182/blood-2022-158143
Published: 2022